[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100315001":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":25,"locations":35,"responsibleParty":48,"collaborators":51,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":25,"overallStatus":73,"whyStopped":25,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fraxel Restore on one side of the face","ACTIVE_COMPARATOR","Fraxel Restore on one side of the face\n\nFraxel Restore: acne scar correction\n\nRandomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned.",[13],"Device: Fraxel Restore",{"label":15,"type":10,"description":16,"interventionNames":17},"Fractora on the other side of the face","Fractora on the other side of the face\n\nFractora: acne scar correction\n\nRandomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned.",[18],"Device: Fractora",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Fraxel Restore","Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Fractora","Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.",[15],[31],{"name":32,"affiliation":33,"role":34},"Mathew Avram, MD","MGH","PRINCIPAL_INVESTIGATOR",[36],{"facility":5,"status":25,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":25},"Boston","Massachusetts","02114","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-71.05977,42.35843,{"lat":46,"lon":45},{"type":34,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Mathew Avram, MD, JD","Director, MGH Laser, Cosmetic and Dermatologic Surgery",[52],{"name":53,"class":6},"American Society for Dermatologic Surgery","100315001","comparison-of-1550-nm-laser-and-fractional-radiofrequency-microneedle-for-the-treatment-of-acne-scars-in-ethnic-skin-100315001",true,"NCT03380845","Comparison of 1,550-nm Laser and Fractional Radiofrequency Microneedle for the Treatment of Acne Scars in Ethnic Skin","Comparison of Fractional Erbium-Doped 1,550-nm Laser and a Bipolar Fractional Radiofrequency Microneedle Device for the Treatment of Atrophic Acne Scars in Ethnic Skin: A Randomized Split-Face Controlled Pilot Study","Inclusion Criteria:\n\n* Men and women with Fitzpatrick skin types III through VI and facial acne scarring of grades III-IV will be enrolled. Both sides of the participants' face should have almost similar amount and severity of acne scarring. Participants will be over 18 years old\n\nExclusion Criteria:\n\n* Patients have to be overall healthy without a history of keloidal scarring, localized or active infection in the treatment region, immunodeficiency disorders, porphyria or light sensitivity, and connective tissue disorders. Per PI discretion, any serious medical condition that may interfere with the study. In addition, pregnant or nursing women, patients who have been taking isotretinoin for a period of 6 months before treatment, and patients who have received any cosmetic treatment (lasers, dermabrasion, chemical peels, etc) in the previous 6 months will be excluded. Also, patients with renal disease, and any allergies to Lidocaine, Tetracaine, or Valtrex will be excluded.","ALL","18 Years","65 Years",{"count":65,"type":66},4,"ACTUAL","INTERVENTIONAL",[69],"NA","The primary objective of this randomized, split-face, controlled study is to compare the efficacy and safety of a erbium-doped 1,550-nm non-ablative fractional laser and a bipolar fractional radiofrequency microneedle device for the treatment of atrophic facial acne scars in ethnic skin (Fitzpatrick Skin Phototypes III-VI).\n\nThe hypothesis of this study is that both erbium-doped 1,550-nm non-ablative fractional laser and the bipolar fractional radiofrequency microneedle device are equally effective for the treatment of atrophic acne scars in ethnic skin (SPT III-VI). However, the bipolar fractional radiofrequency microneedle device has less adverse effects than erbium-doped 1,550-nm non-ablative fractional laser due to the absence of scattering and the absence of chromophore-specific targets - predominantly melanin - traditionally needed with laser treatments; hence the fractional radiofrequency microneedle device will have a higher safety profile in darker skin types .",[72],"Acne Scars","COMPLETED","2019-11-17",{"date":76,"type":66},"2019-11-19",{"date":78,"type":66},"2018-03-16",{"date":80,"type":66},"2018-10-30",{"name":5,"class":6},1]